• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results

    Gabrielle Lakusta
    Feb. 28, 2018 08:57AM PST
    Pharmaceutical Investing

    MannKind (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: For the fourth quarter of 2017, Afrezza net revenue was $4.5 million, an increase of 125% compared to the third quarter of 2017 and 238% compared to the fourth quarter of 2016.  Included in …

    MannKind (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2017.

    As quoted in the press release:

    For the fourth quarter of 2017, Afrezza net revenue was $4.5 million, an increase of 125% compared to the third quarter of 2017 and 238% compared to the fourth quarter of 2016.  Included in the fourth quarter net revenue is a favorable adjustment for a change in estimate of $1.4 million. The change in estimate relates to obtaining new and more comprehensive data regarding the inventory in the distribution channel – specifically inventory in the retail channel.

    Click here to read the full press release.

    pharmaceutical investingfinancial results
    The Conversation (0)

    Go Deeper

    AI Powered

    KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance

    Test tubes.

    Amgen, Merck and Pfizer Release Latest Quarterly Earnings, Share 2025 Plans

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    InMed Pharmaceuticals

    InMed Pharmaceuticals (INM)
    INM

    Cardiol Therapeutics

    Cardiol Therapeutics (CRDL:CC)
    CRDL:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES